1993 年 15 巻 1 号 p. 57-64
Employing a monoclonal antibody-based two-site enzyme immunoassay method for basic fibroblast growth factor, we measured immunoreactive bFGF levels in sera of patients with breast cancer, and found that the level of immunoreactive bFGF was significantly increased in sera of most of the patients. Two immunoreactive peaks were observed in the fractions of sera of the normal subjects and the patients with breast cancer by HPLC size-exclusion chromatography: one peak eluted at the void volume; and the other, at the same position as that of standard recombinant bFGF. This result suggests that bFGF-like immunoreactive substance of high molecular (HMW bFGF-LI) together with normal bFGF exists in sera of normal subject and patients with breast cancer. The amount of HMW bFGF-LI of the patient was considerably larger than that of the normal subject, and the former decreased to the normal level after surgical resection of the tumor region.
